<DOC>
	<DOCNO>NCT02161939</DOCNO>
	<brief_summary>The primary objective program provide DCV 24 week give combination SOF subject chronic hepatitis C decompensated cirrhosis post-liver transplant subject chronic hepatitis C recurrence either advance fibrosis fibrosing cholestatic hepatitis serious immediately life-threatening condition experience event decrease life expectancy &lt; 12 month , therefore , research hypothesis test specific endpoint define . However , safety data collect throughout study well efficacy data</brief_summary>
	<brief_title>A Multicenter Treatment Protocol Daclatasvir ( BMS-790052 ) Combination With Sofosbuvir Treatment Post-Liver Transplant Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients chronically infected Hepatitis C Subjects receive liver transplant , chronic hepatitis C virus ( HCV ) recurrence advanced fibrosis ( Metavir F3F4 ) fibrosing cholestatic hepatitis Subjects decompensated cirrhosis define ChildPugh Class C Patients &lt; 18 year old Clinical pathologic evidence acute ongoing liver graft rejection Creatinine clearance ( CrCl ) â‰¤30 mL/min ( estimate Cockcroft Gault formula ) Patients contraindication either Daclatasvir ( DCV ) Sofosbuvir ( SOF ) Patients pregnant Women Child Bearing Potential use require contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>